Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2024; 12(11): 1918-1928
Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1918
Chaiqin Chengqi Decoction as an adjuvant treatment for mild/moderately severe hypertriglyceridemic acute pancreatitis: A retrospective study
Hai-Fu Zhang, Ze-Xuan Su, Yong-Hang Feng, Shuo-Jun Li, Bi-Yun Xie
Hai-Fu Zhang, Ze-Xuan Su, Yong-Hang Feng, Shuo-Jun Li, Bi-Yun Xie, Department of Internal Medicine, The First People's Hospital of Fuyang, Hangzhou 311400, Zhejiang Province, China
Co-first authors: Hai-Fu Zhang and Ze-Xuan Su.
Author contributions: Zhang HF and Su ZX contributed equally to this work as co-first authors; Zhang HF and Su ZX carried out data curation; Zhang HF and Xie BY were responsible for designing the research study and writing the paper; Feng YH and Li SJ conducted data analysis and completed the visualization process.
Supported by The Hangzhou Science and Technology Bureau, No. B20230285.
Institutional review board statement: This study is a retrospective study, and the use of patient clinical data has passed ethical review, ethical review No. 2022-lw (031).
Informed consent statement: The study received approval from the institutional review board of The First People's Hospital of Fuyang, and the requirement for informed consent was waived.
Conflict-of-interest statement: The authors declare that there are no competing interests associated with the manuscript.
Data sharing statement: The data that support the findings of this study are not publicly available due to their containing information that could compromise the privacy of research participants but are available from the corresponding author Bi-Yun Xie upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bi-Yun Xie, MD, Doctor, Department of Internal Medicine, The First People's Hospital of Fuyang, No. 429 Beihuan Road, Fuchun Street, Fuyang District, Hangzhou 311400, Zhejiang Province, China. angisxie@163.com
Received: November 26, 2023
Peer-review started: November 26, 2023
First decision: January 24, 2024
Revised: February 6, 2024
Accepted: March 20, 2024
Article in press: March 20, 2024
Published online: April 16, 2024
Processing time: 136 Days and 17.7 Hours
ARTICLE HIGHLIGHTS
Research background

Hypertriglyceridemia is currently the third leading cause of acute pancreatitis (AP), with its incidence continuing to rise. Moreover, there exists a positive correlation between the severity of pancreatitis and elevated levels of triglycerides (TG). Notably, Chaiqin Chengqi Decoction (CQCQD) has been historically employed in our country for the treatment of AP.

Research motivation

CQCQD has a rich historical background in the management of pancreatitis in China. The lipid-lowering effects of certain Traditional Chinese Medicine components have been observed in previous research. In order to validate its efficacy in treating hypertriglyceridemic AP (HTG-AP) and facilitate its clinical implementation, we conducted a retrospective study.

Research objectives

To assess the impact of CQCQD on blood lipid levels and clinical manifestations in patients with mild, mild/moderately HTG-AP.

Research methods

The clinical data of 39 patients with HTG-AP admitted to our hospital between January 2019 and November 2020 were retrospectively analyzed. We conducted a comparative analysis of changes in blood lipids, gastrointestinal symptoms, and abdominal computed tomography (CT) findings before and after treatment between the two groups.

Research results

Twenty patients were treated with conventional HTG-AP regimen, and 19 patients were additionally treated with CQCQD. After receiving treatment, the TG level of the CQCQD group was lower than that of the CQCQD group (3.14 ± 0.25mmol/L vs 4.96 ± 0.47 mmol/L, P < 0.01). However, there were no significant differences observed in other lipid parameters, including total cholesterol, high-density lipoprotein cholesterol, and apolipoprotein B, between the two groups. After 3 d of treatment, the patients in the CQCQD group had more bowel movements than the control group (2.51 ± 0.25 times vs 1.00 ± 0.17 times, P = 0.01). The gastrointestinal function of most patients returned to normal, and AGI was significantly lower than that of the control group (0.11 ± 0.07 vs 0.42 ± 0.11, P < 0.01). The CT reexamination conducted after 3-5 d of treatment revealed no significant difference in Balthazar score between the two groups (2.44 ± 0.70 vs 2.29 ± 0.69, P = 0.53).

Research conclusions

In HTG-AP patients, CQCQD can significantly reduce the TG level, shorten the recovery time of defecation, significantly improve the gastrointestinal function.

Research perspectives

More data are required for a more comprehensive analysis in future investigations. Simultaneously, it is imperative to conduct fundamental experiments to elucidate the underlying mechanism of CQCQD.